Clinical trial NCT06627517: Safety and Effectiveness of the Luna System in People with Type 1 Diabetes Mellitus
Official title: Automated Insulin Delivery for Multiple Daily Injectors (AID4MDI)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Type 1 Diabetes Mellitus
Sleep Quality
Keywords: overnight hyperglycemia
sleep quality
type 1 diabetes
closed loop
Lead sponsor: Luna Diabetes
Sponsor class: INDUSTRY
First posted: 2024-10-04
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to evaluate the effect of a wearable insulin pump on blood sugar levels during sleep. The study device works with continuous glucose monitors (CGM) to calculate and deliver rapid-acting insulin doses during sleep. The study device does not replace long-acting, correction, or mealtime insulin. The study will involve applying the study device before bed for a period of 13 weeks. The overall study length is approximately 17 weeks.

The study aims to evaluate whether the study device is safe and if it lowers blood sugar levels in people who have consistently high blood sugar during sleep and at wake.


Eligibility criteria: Inclusion Criteria

1. ≥18 years of age at time of consent
2. Clinical diagnosis of T1D for ≥ 6 months with a stable insulin regimen for ≥ 30 days.
3. Using a basal-bolus regimen with multiple daily injections of insulin or doses of inhaled insulin for ≥ 3 months with a stable basal dosing regimen over the previous 30 days
4. If using a non-insulin glucose-lowering drug, (e.g. GLP-1 agonists, SGLT2 inhibitors), must have a stable dose for ≥ 30 days
5. If using a weight loss medication, must be on a stable dose for ≥ 30 days
6. Using insulin lispro or insulin aspart as bolus insulin or able to obtain for the duration of the study

5. If using a weight loss medication, must be on a stable dose for ≥ 30 days 6. Using insulin lispro or insulin aspart as bolus insulin or able to obtain for the duration of the study 7. Using CGM (real-time or intermittent scanning) for ≥ 3 months (with at least 50% use), and at least 85% use in the prior 14 days 8. Using Dexcom G6 or able to obtain for the duration of the study 9. Using an iPhone as part of daily life or able to obtain for the duration of the study 10. Recurrent nocturnal hyperglycemia, defined as ≥ 7 of the previous 14 days with a nighttime glucose value \> 180 mg/dL.

* Nighttime is defined at the discretion of the investigator and is intended to be the time period from when the subject goes to bed to when they get up in the morning 11. Negative baseline pregnancy test. Females of childbearing potential, willing to use an adequate method of birth control for the duration of the study.
* Adequate methods of birth control include hormonal contraceptives, intrauterine devices, or double barrier contraception, e.g., condom + diaphragm, condom or diaphragm + spermicidal gel, or foam.
* Menopause is defined as one year without menses; if in question, a follicle stimulating hormone of \>40 U/ml must be documented.
* Hysterectomy, bilateral oophorectomy, or bilateral tubal ligation must be documented as applicable.

  12. Availability of a relative or acquaintance residing within 15 minutes of the subject and willing to be the subject's care partner throughout the study.
* The care partner must be willing to be trained on how to use the Dexcom Follow app and administer glucagon.
* The care partner must be willing to contact the subject upon a low or high alarm, provide aid to the subject, including glucagon administration, and/or contact emergency services.

  13. Willing to share access to CGM data with the Sponsor through the Dexcom Clarity app 14. No medical, psychiatric, or other conditions, or medications being taken that in the Investigator's judgement would be a safety concern for participation in the study. This includes considering the potential impact of medical conditions known to be present including cardiovascular, liver, kidney disease, thyroid disease, adrenal disease, malignancies, vision difficulties, active proliferative retinopathy, and other medical conditions; psychiatric conditions including eating disorders; drug or alcohol abuse.

Exclusion Criteria

1. Use of or plan to use insulin pump therapy during the study period.
2. Use of basal insulin for ≥ 60% of the total daily insulin dose on average over the last week per subject report.
3. Pregnant, lactating, or plans to become pregnant in the next 17 weeks. A negative serum or urine pregnancy test is required for all females of child-bearing potential.
4. Known stage 4/5 renal failure or on dialysis
5. Using Hydroxyurea medication
6. Current or anticipated acute use of corticosteroids (other than topical or inhaled) or other medications that have a known effect on glycemic variability during the time period of the study
7. Anticipated initiation of a weight loss medication and/or titration during the study period
8. Alcohol or drug use that would reduce sensitivity to symptoms of hypoglycemia or hinder appropriate decision-making in the judgment of the investigator.
9. Use of electrically powered implant(s) that may be susceptible to RF interference, such as cardiac pacemakers, spinal cord stimulators, or implantable cardioverter-defibrillators.
10. Severe hypoglycemia (defined as requiring 3rd party assistance and/or loss of consciousness or seizure) within 90 days prior to screening.
11. Diabetic ketoacidosis (DKA) diagnosed at a health care facility within 90 days prior to screening
12. Use of an investigational drug in the 30 days prior to screening.
13. Employed by or has immediate family members employed by Luna Health; is directly involved in conducting the clinical study; has a direct supervisor at the place of employment who is also directly involved in conducting the clinical study (as a study investigator, coordinator, etc.); or has a first-degree relative who is directly involved in conducting the clinical study.

Primary outcomes:
measure: Severe hypoglycemia events
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Diabetic ketoacidosis events
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Change in CGM-measured time in range (70-180 mg/dL)
timeFrame: From device activation to the end of treatment at 13 weeks
Secondary outcomes:
measure: Change in CGM-measured percentage of time > 180 mg/dL
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Change in CGM-measured percentage of time > 250 mg/dL
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Change in CGM-measured percentage of time waking in range (70-180 mg/dL)
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Change in CGM-measured fasting glucose at the end of the sleep period
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Change in Pittsburgh Sleep Quality Index (PSQI) score
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Change in HbA1c
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Change in Epworth Sleepiness Scale (ESS) score
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Rate, severity, and device-relatedness of all adverse events
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Change in CGM-measured time < 70 mg/dL
timeFrame: From device activation to the end of treatment at 13 weeks
measure: Change in CGM-measured time < 54 mg/dL
timeFrame: From device activation to the end of treatment at 13 weeks
Other outcomes:
Locations:
city: Walnut Creek
country: United States
facility: Diablo Clinical Research
state: California
city: Aurora
country: United States
facility: Barbara Davis Center for Diabetes
state: Colorado
city: Minneapolis
country: United States
facility: International Diabetes Center
state: Minnesota
Study officials:
affiliation: University of California, San Diego
name: Jeremy H Pettus, MD
role: PRINCIPAL_INVESTIGATOR
References: